secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2026-08-14T13:00:38+00:00
Accession:  0001178913-26-004136
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion Q2 net loss widens to $3.6M; Phase 2/3 trial initiated
---------------------------------------------------------------

- Q2 net loss $3.6M vs $2.5M YoY; R&D up 120% to $2.2M on trial prep.
- Six-month net loss $6.3M vs $4.2M; cash $2.2M at June 30, down from $6.0M.
- Closed Aug 13 public offering gross $2.5M, net $2.1M; equity est. $3.2M, restoring Nasdaq compliance.
- Phase 2/3 SIL204 trial initiated July 29 at Tel Aviv Sourasky; approvals from Germany BfArM and Israel.
- 1-for-10 reverse split May 28, 2026; preclinical data supports immune-sensitization across 4 KRAS mutations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326004136/0001178913-26-004136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326004136/zk2635972.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-004136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer